cases % alive Beam directed Pre-supervoltage X-ravs . 37 30 % 35 Y, Radium beam 11 55 4 MV linear accelerator 22 7 77°/0
beam directed X-rays. There is a further increase to 77 % for the 4 MV cases. When the beam directed X-rays are added to the radium beam cases a "pre-supervoltage" group is formed. The survival rate at two years for this group is more than doubled by those treated by supervoltage. It has already been said that five-year figures are not yet available for supervoltage. However, it has also been shown for all radically treated patients, that there is a difference of only 6% between the two-and five-year survival rates. As there is no reason to suppose that the pattern of survival will change with the new treatment, the relationship between the supervoltage cases at two and five years should remain the same as before.
The increase from 35 % for the pre-supervoltage group to 770% for supervoltage (or 4 MV) is so striking that doubt may arise as to the validity of the comparison. Evidence is given below to show that the two groups are very similar in their composition.
Age It will be remembered that only those patients treated radically are included in the two groups.
The figures of 62 % for the pre-supervoltage group and 81 % for the 4 MV group show that there has been no bias towards selecting only a few of the total group seen for treatment on the supervoltage machine. Rather the tendency has been to accept patients for the accelerator who had more advanced disease than previously would have been considered for radical treatment. This trend has been noticed in diseases other than cancer of the middle ear in relation to supervoltage treatment. Therefore, it is likely from these comparisons that the two groups are similar in regard to the material which constitutes them and that those treated by supervoltage do not form a selected series of early cases.
Conclusions.-Thus the evidence is strong that the treatment of carcinoma of the middle ear by the 4 MV linear accelerator does represent a significant advance over that by other methods. It is hoped and expected that when five-year figures become available, there will be a marked increase in the percentage of survivors. Bladder Carcinoma
Manchester THE bladder is a relatively deep-seated organ, mainly surrounded by bone, lying in close relation to the other pelvic organs; moreover, tumours of the bladder are of limited radiosensitivity and require high doses if cure is to be obtained. Even with the use of elaborate multifield and rotational techniques, treatment with conventional 250-300 kV X-ray therapy is difficult and entails the production of severe reactions to deliver an adequate tumour dose. Before the introduction of the 4 MV linear accelerator, the majority of radical X-ray treat-ments of bladder tumours at the Christie Hospital were carried out on a 500 kV constant potential machine of H.V.L. 6-3 mm Cu. With this quality of X-irradiation, the bone shielding was significantly less than with conventional 250-300 kV irradiation and not greatly different from 4 MV irradiation. Even so, to deliver an adequate dose at the bladder required the use of a complex multifield treatment technique.
When introducing a new machine into routine clinical practice, the method of use will be influenced mainly by past experience with the type of lesion to be treated, and what evidence, both clinical and experimental, has accumulated during the trial period before its acceptance into routine use. As experience increases, alterations and adjustments will be made as the treatment technique develops. Once the technique and dosage has been established, the method of comparison of results has to be determined.
The routine use of the linear accelerator for the radical treatment of bladder tumours was begun in 1955; I shall discuss our experience in the first two years of its use and present the results of patients treated in 1955 and 1956 as assessed at three years. All patients were treated with the same technique and to the same dosage levels.
The selection of patients for treatment was as follows: All early bladder carcinomata, i.e. mucosal and muscular tumours up to a circle of 4 cm diameter, were treated by means of permanent radon seed implants, and this policy has been rigidly adhered to. Metastatic tumours and tumours with gross pelvic fixation were treated palliatively. The remainder, including multiple mucosal tumours, were treated radically provided that the general condition was adequate. This group included both untreated patients and recurrent and residual tumours following surgery.
Bladder tumours are of limited radiosensitivity, and the principle of small volume high dose has been adhered to. No deliberate attempt was made to treat the whole bladder except when there were multiple tumours involving most of the surface of the organ, nor was any attempt made to include the regional lymph nodes in the treatment volume. The field sizes used were 8 x 6 cm or the equivalent area for small lesions and 10 x 8 cm or the equivalent area for larger lesions.
For this type of treatment accurate localization of the tumour is essential. Localization is based on the combination of the cystoscopic and examination under anesthesia findings, and the use of cystograms. The best method of localization is undoubtedly to insert inactive gold seeds cystoscopically to demarcate the limits of the tumour; furthermore, if this has been done, verification radiographs through one of the treatment fields taken either on the linear accelerator or a simulator unit can be made. Failing this, the usual cystograms are made using a weak barium suspension as the opaque medium. The position of the tumour relative to anterior and posterior skin markers is determined.
The treatment technique adopted was a 3-field symmetrical arrangement with 1 anterior field and 2 posterolateral fields. Beam direction was carried out as follows:
There is no actual pin and arc on the linear accelerator but by virtue of its design to rotate isocentrically the machine acts as its pin and arc. The linear accelerator is designed to rotate about a point 1 metre from the focal spot. Thus if the tumour is placed 1 metre from the focal spot then the machine rotates about the tumour. Even with the linear accelerator, it is still felt that compression is worth while and to obtain this we use a telescopic Perspex applicator on which the F.S.D. can be read. The end of the applicator is closed by a sheet of 3 mm Perspex which does not greatly diminish the skin sparing effect of a 4 MV irradiation.
For fields of area up to 50 sq. cm, the dose given was 6,000 rads and for areas up to 80 sq. cm 5,500 rads in three weeks.
In the years 1955-1956, 87 patients were treated radically on the linear accelerator, of whom 60 were previously untreated, and 27 recurrent or residual. 83y% were histologically proven.
Of the 87 treated, 25 or 29 % are alive at three years; of these, 22 were histologically positive: one has had a total cystectomy (Table I [1953] [1954] , that is pre-megavoltage, 97 bladder tumours were treated with radical X-ray therapy with a three-year crude survival rate of 27%. Fig. 1 shows the survival curves for the two groups, i.e. 1953-1954 pre-megavoltage treatment, and 1955-1956 the two megavoltage groups are small and the difference in the results in these groups is not statistically significant in the orthodox sense, although they show promise. Retrospective staging of the cases in the two years involved did not indicate that the criteria of selection had altered between them. The only change in technique was a slight increase in the field sizes used. It would seem probable that the difference is due to more familiarity with the machine and possibly to improvement in localization methods. Symptoms due to bladder reactions have not been severe. It has been exceptional for a patient to have much dysuria or strangury during treatment. Clinical impression was at first that the symptoms were less than was found with the 500 kV cases, but I do not think there is any significant difference.
A small number of 4 MV and 500 kV treated patients were cystoscoped at varying periods after completion of treatment in an effort to compare the bladder mucosal reactions; however, nothing conclusive came of this investigation.
Unless the tumour is very anteriorly placed, it is difficult not to produce some degree of rectal reaction on treating a bladder tumour radically with external irradiation. The severity of the symptoms varies from patient to patient. Clinical impression has been that the degree of reaction with the 4 MV radiation has been less severe than with 500kV X-ray, as might be expected from the field distribution and the smaller volume of the pelvis raised to high dose.
In this series of 87 patients, there has been one example of severe bowel injury:
Male, aged 70. Cystoscopy revealed on the posterior wall of the bladder a solid nodular tumour 4-5 cm in diameter; the margins were ill-defined. Per rectum the prostate was very hard and suggestive of a carcinoma on left side; a tumour was palpable on the posterior wall of bladder, forming a plaque 5 cm in diameter. Treatment was given on the linear accelerator, using 8 x 8 cm fields to a dose of 6,000 rads in three weeks. Towards the end of the course he developed diarrhoea, which continued after the completion of treatment. Sigmoidoscopy approximately one month later revealed that at 10-15 cm the rectal wall was indurated and the instrument could not be passed further. Diarrhrea persisted, and two months after completion of treatment he developed signs of peritonitis and died. Autopsy revealed perforation of a necrotic area of pelvic colon.
No other case of large or small bowel injury occurred in this series. So far we have not observed any evidence of late complications such as severe bleeding from telangiectasia or contracted bladder. These late complications are in our experience uncommon with external irradiation of bladder tumours.
In the first two years of the routine clinical use of the linear accelerator in the treatment of bladder tumours, a treatment method was evolved which has proved easy to use, and which has enabled radical treatment without the production of severe reactions or complications. The early results would seem to support the contention that with the introduction of a new machine producing radiation, the relative biological efficiency of which is not fully known initially, the results will not be better than those obtained with well-established, orthodox treatment. As experience with the clinical use of the machine increases, results should improve.
With the acceptance of an R.B.E. of 85: 100, the dose was increased in 1957 so that for fields of area up to 50 sq. cm the dose became 6,500 rads, and for the larger fields 6,000 rads in three weeks. With these dose levels, there has been no noticeable increase in the severity of reactions, nor have any significant complications occurred.
In order to compare the results of 4 MV treatment with 500 kV treatment of bladder tumours, it was decided to run a clinical trial. In view of the number of variables, a properly conducted random selection trial was decided upon. For the past three years, untreated cases of bladder tumours suitable for radical X-ray therapy have been divided into two groups, one group receiving 500 kV irradiation, and the other 4 MV irradiation. This trial has not been running long enough to report on.
To summarize, with the 4 MV linear accelerator, radical X-ray treatment of bladder tumours has become simpler and less wearing to the patient. Initial results of treatment have been satisfactory, but a full assessment in comparison with the previous method of treatment depends on the findings of the random selection trial now proceeding.
